Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2005

View Archived Issues

EpiCept and Maxim to merge

Miconazole Lauriad cleared for phase III trial for oropharyngeal candidiasis

Chiron rejects Novartis' offer

Canadian phase II study for ragweed allergy vaccine

Phase III program begins for alfimeprase in central venous catheter occlusion

ReGen acquires rights to new use for zolpidem

Cytokinetics begins phase I trial with CK-1827452 for acute heart failure

Hemispherx reports preclinical studies on dsRNA

Xigen concludes Series A financing

Pharmos studies cannabinor in phase I trial

EOquin enters new phase II study for high-risk superficial bladder cancer

ViroLogic changes name to Monogram Biosciences

Kinex selects KX2-377 as lead drug candidate for oncology

Liponex develops improved formulation of CRD5

FDA Committee recommends approval of Orencia for rheumatoid arthritis

Recent Bristol-Myers Squibb patent discloses new treatments for migraine

New agents for treating obesity claimed

Recent patent describes novel antimalarial agents

New therapeutic agents for renal diseases in early development at Astellas Pharma

GSK-171B: A novel MC4R agonist

JNJ-27301937 depletes macrophages from arthritic joints in mice

ABX-10-0031 neutralizes IL-1beta and blocks production of IL-6 in vitro and in vivo

BL-5160: A novel HNE inhibitor with therapeutic potential for COPD

RSD-1235 shows greater efficacy in inducing conversion of recent-onset AF

RDP-58 effective in models of acute and chronic contact dermatitis

In vivo studies reveal potential of photosensitizer RLP-068 in cutaneous diseases

A phase II study supports the use of fesoterodine in overactive bladder

Therapeutic benefits of efaproxiral in patients with locally advanced NSCLC

Webcasts from ICS Annual Meeting now available

Prous Science and ESC webcast over 25 sessions from ESC Congress 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...